Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) will be hosting a conference call at 4:30 PM eastern time on 11th August 2020, to discuss its 2Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.cumberlandpharma.com
Earnings Expectation
Cumberland Pharmaceuticals Inc. is reporting second quarter earnings results on Tuesday 11th August 2020, after market close. The consensus estimates from Thomson Reuters are income of $ 0.03 per share from $ 9.27 million in revenue. For the full year, analysts predict revenues of $ 39.21 million, while looking forward to income of $ 0.14 per share.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The companys Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.
